Hormel Foods (HRL) Q3 Earnings Miss Estimates

Hormel Foods (HRL) reported Q3 earnings of $0.35 per share, missing the Zacks Consensus Estimate of $0.41 by 14.63%, and declining from $0.37 year-over-year. Despite this earnings miss, the company's revenues reached $3.03 billion, surpassing consensus by 1.90%. Hormel has consistently failed to meet EPS estimates over the past four quarters, and its shares have underperformed the S&P 500 year-to-date, leading to a Zacks Rank #4 (Sell) and signaling potential continued underperformance within a challenging industry.

Analysis

Hormel Foods (HRL) reported mixed results for its third quarter, characterized by a significant earnings shortfall alongside a modest revenue beat. The company posted adjusted earnings of $0.35 per share, a 14.63% miss against the Zacks Consensus Estimate of $0.41 and a decline from $0.37 in the prior-year period. This marks the fourth consecutive quarter that Hormel has failed to surpass consensus EPS estimates, signaling persistent challenges in profitability or cost management. On the top line, quarterly revenues of $3.03 billion surpassed the consensus estimate by 1.90% and grew from $2.9 billion year-over-year, although the company has only managed to top revenue forecasts twice in the last four quarters. The stock's performance reflects these fundamental weaknesses, having lost 7.5% year-to-date in contrast to the S&P 500's 10.2% gain. Compounding these issues, the pre-earnings analyst sentiment was already unfavorable, resulting in a Zacks Rank of #4 (Sell) and placing Hormel within the poorly performing Food - Meat Products industry, which ranks in the bottom 29% of over 250 Zacks industries.

Key Decisions for Investors

• Given the substantial earnings miss, a history of failing to meet EPS estimates, and a pre-existing 'Sell' rating, investors should anticipate continued downward pressure on HRL's stock price in the near term.
• The key catalyst for any change in outlook will be management's commentary on the earnings call; focus specifically on explanations for margin compression and any revisions to future guidance, as this will dictate analyst estimate revisions.
• Considering the stock's significant underperformance against the S&P 500 and the weak industry backdrop, it may be prudent to re-evaluate exposure to HRL, as the modest revenue growth appears insufficient to offset the more critical profitability concerns.